European CHMP recommends approval of nitisinone for the treatment of alkaptonuria in adults

If approved, this will be the first licensed treatment for alkaptonuria, a rare disorder affecting one in every 250,000 to 1 million people, characterised by the inability of the body to metabolize homogentisic acid (HGA) due to the lack of an enzyme.


European Medicines Agency